[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
May 22, 2006

Clinical Trials Are Required to Prove the Chemopreventive Worth of Statins

Arch Intern Med. 2006;166(10):1143. doi:10.1001/archinte.166.10.1143-a

The recent article by Eliassen et al1 found no breast cancer risk reduction among statin users from the Nurses Health Study (n = 75 828). However, there is inadequate data on type of statin use—lipophobic statins have been shown to have little effect on cancer growth in vitro or in vivo and should not be included in the analysis.2 Furthermore, dose-duration effects were not considered, and data were based on self-reporting.